
|Videos|April 29, 2020
CAR T-Cell Therapy During the COVID-19 Pandemic
Advertisement
This OncLive® webinar will focus on the impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor (CAR) T cells. We will feature a panel of leading experts to discuss important topics and considerations surrounding CAR T-cell therapies and the patient populations impacted during this time.
Topics:
- Resources for safe administration of CAR T-cell therapy
- Patient selection for the receipt of CAR T-cell therapy in the COVID-19 setting
- Supportive care and services for patients receiving therapy during the COVID-19 pandemic
- Impact on the continuation and enrollment of clinical trials involving CAR T-cell therapies and implications for patients
Sponsored by: Novartis
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5



































